T Cell Immunotherapy News

This is selected news for T Cell Immunotherapy, which is filed under Healthcare Topics. There are 93 news items for this page. A press release filter page is also available for T Cell Immunotherapy.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
11/24/2022 Global CAR-T Cell Immunotherapy Market Research Report 2022 - Market Size, Current Insights and Development Trends
CAR T-Cell Immunotherapy market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global CAR T-Cell Immunotherapy market will be able to gain the upper hand as they use the rep... CAR-T Cell Immunotherapy market is segmented by ...
reportsnreports.com
11/14/2022 PDS Biotech Announces 100% Clinical Response in Cervical Cancer Patients in Preliminary Data from IMMUNOCERV Phase 2 Clinical Trial
... the public on November 7. The enhanced data was presented in the poster titled, ‚AuIMMUNOCERV, an Ongoing Phase II Trial Combining PDS0101, an HPV-Specific T Cell Immunotherapy, with Chemotherapy and Radiation for Treatment of Locally Advanced Cervical Cancers,‚Au which highlights key findings from The University of Texas MD ...
Yahoo News
11/14/2022 PDS Biotech Announces 100% Clinical Response in Cervical
... the public on November 7. The enhanced data was presented in the poster titled, ‚AuIMMUNOCERV, an Ongoing Phase II Trial Combining PDS0101, an HPV-Specific T Cell Immunotherapy, with Chemotherapy and Radiation for Treatment of Locally Advanced Cervical Cancers,‚Au which highlights key findings from The University of Texas MD ...
Globe Newswire
11/14/2022 PDS Biotech Announces 100% Clinical Response in Cervical Cancer Patients in Preliminary Data from IMMUNOCERV Phase 2 Clinical Trial
... the public on November 7. The enhanced data was presented in the poster titled, "IMMUNOCERV, an Ongoing Phase II Trial Combining PDS0101, an HPV-Specific T Cell Immunotherapy, with Chemotherapy and Radiation for Treatment of Locally Advanced Cervical Cancers," which highlights key findings from The University of Texas MD Anderson ...
knowledia.com
11/9/2022 Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Demonstrating NKTR-255, a Novel Polymer-conjugated Human IL-15, Improves Efficacy of CD19-targeted CAR-T Cell Immunotherapy
Polymer-conjugated IL-15 (NKTR-255) induced CD8 + T cell and natural killer cell proliferation in vivo -- -- NKTR-255 enhanced the efficacy of human CD19 CAR-T cells in a xenogeneic lymphoma model -- SAN FRANCISCO , Nov. 9, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced the publication of preclinical data ...
PR Newswire
10/11/2022 » China's NMPA approves sNDA for JW Therapeutics’ follicular lymphoma therapy
... in 24 months of second-line or above systemic treatment (r/r FL). Developed by JW Therapeutics, relma-cel is an autologous anti-CD19 CAR-T cell immunotherapy product which has been developed based on Juno Therapeutics‚Ao CAR-T cell process platform. The regulatory approval marks relma-cel as ...
pharmaceutical-business-review.com
10/10/2022 JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in Patients with Relapsed or Refractory Follicular Lymphoma
... r FL). This is the second approved indication for relma-cel following its initial approval and launch in September last year, and makes it the first cell immunotherapy product approved in China for the treatment of r/r FL patients. This approval is based on the 6 months clinical results ...
PR Newswire
10/10/2022 JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in Patients with Relapsed or Refractory Follicular Lymphoma
... r FL). This is the second approved indication for relma-cel following its initial approval and launch in September last year, and makes it the first cell immunotherapy product approved in China for the treatment of r/r FL patients. This approval is based on the 6 months clinical results ...
prnasia.com
10/10/2022 JW Therapeutics receives approval for relapsed or refractory follicular lymphoma drug
... r FL). This is the second approved indication for relma-cel following its initial approval and launch in September last year, and makes it the first cell immunotherapy product approved in China for the treatment of r/r FL patients. This approval is based on the six months clinical results ...
labiotech.eu
10/5/2022 Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
... November 8-12, 2022 in Boston, MA. Poster Presentations: Abstract Title: Innate-Enhanced Chimeric Adaptors (CAd): A Newly-Described Approach for Augmenting Potency of Œ≥Œ¥ T Cell Immunotherapy Poster/Abstract Number: 198 Presenting Author: Marissa Herrman, Ph.D. Date / Time: November 11, 2022 from 9:00am ‚Ai 9:00pm EST Title: Preclinical Discovery ...
Business Wire
9/28/2022 Verismo Therapeutics Receives U.S. FDA Orphan Drug Designation for SynKIR-110‚Ñ¢, a First-in-Class KIR-CAR T Cell Immunotherapy Candidate, for the Treatment of Mesothelioma
Next-gen approach to cell therapy targeting solid tumors powered by the KIR-CAR platform PHILADELPHIA , Sept. 28, 2022 /PRNewswire/ -- Verismo Therapeutics , a clinical-stage CAR-T company and Penn spinout, and pioneer of the novel KIR-CAR platform technology, today announced that the U.S. Food and Drug Administration (FDA ...
PR Newswire
9/20/2022 Verismo Therapeutics Announces FDA Clearance of IND Application for SynKIR-110‚Ñ¢, a KIR-CAR T Cell Immunotherapy Candidate
Verismo Therapeutics Announces FDA Clearance of IND Application for SynKIR-110‚N¢, a KIR-CAR T Cell Immunotherapy Candidate Company to initiate Phase 1 of the first-ever clinical trial for KIR-CAR T cells in Q1 2023 PHILADELPHIA, Sept. 20, 2022 /PRNewswire/ Verismo Therapeutics, a clinical-stage biotechnology ...
asapbusinessandcorporatenews.com
9/20/2022 Verismo Therapeutics Announces FDA Clearance of IND Application for SynKIR-110‚Ñ¢, a KIR-CAR T Cell Immunotherapy Candidate
20 Sep 2022 Verismo Therapeutics Announces FDA Clearance of IND Application for SynKIR-110‚N¢, a KIR-CAR T Cell Immunotherapy Candidate [Press Release] Company to initiate Phase 1 of the first-ever clinical trial for KIR-CAR T cells in Q1 2023 PHILADELPHIA, Sept. 20, 2022 /PRNewswire/ Verismo ...
businessandtechnologynewsasap.com
9/20/2022 Verismo Therapeutics Announces FDA Clearance of IND Application for SynKIR-110‚Ñ¢, a KIR-CAR T Cell Immunotherapy Candidate
Company to initiate Phase 1 of the first-ever clinical trial for KIR-CAR T cells in Q1 2023 PHILADELPHIA , Sept. 20, 2022 /PRNewswire/ -- Verismo Therapeutics , a clinical-stage biotechnology company and a Penn -spinout behind the novel KIR-CAR platform technology, today announced that is has received clearance of ...
PR Newswire
8/25/2022 Regen BioPharma Develops Novel Means of Using CAR-T cell Immunotherapy to Attack Solid Tumors
Company Develops A Two-Step Sequential Approach SAN DIEGO , Aug. 25, Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today development of a novel immunotherapy for treatment of solid tumors. Current cellular approaches to kill cancer involve administration of a specific type of modified T cell called ...
PR Newswire
8/10/2022 ELIAS Animal Health Research Demonstrates Cancer-Killing Capabilities of Its Activated T Cell Immunotherapy
In vitro study of the ELIAS Cancer Immunotherapy (ECI ¬AE ) showed personalized T cell immunotherapy initiated a significant immune response against target cancer cells. OLATHE, Kan. , Aug. 10, 2022 /PRNewswire/ -- ELIAS Animal Health recently presented new mechanism of action data for the ELIAS Cancer Immunotherapy (ECI ¬AE ) at the 2022 ...
PR Newswire
5/24/2022 Cancer Cell Paper Identifies "Avidity Enhancement" As New Strategy for Improving CAR T Therapy for Acute Myeloid Leukemia
... announced the publication in Cancer Cell of preclinical research identifying "Avidity Enhancement" as a new strategy to improve therapeutic outcome of Chimeric Antigen Receptor (CAR) T cell immunotherapy in Acute Myeloid Leukemia (AML) . AML poses significant clinical challenges due to its resistance to therapies and its bleak prognosis. Approximately 20,000 ...
PR Newswire
5/7/2022 Life sciences news: Adaptive reveals data on Lyme disease test; mental health startup lands $10M
Provided by Geekwire Seattle Children's is partnering with Umoja Biopharma to test a new CAR T cell immunotherapy in patients with sarcoma, a form of bone cancer. (Seattle Children's Photo) Here's a rundown of the top life sciences and health news across the Pacific Northwest this week ...
MSN
5/5/2022 AlloVir Reports First Quarter 2022 Financial Results
WALTHAM, Mass.--(BUSINESS WIRE)--May 5, 2022-- AlloVir, Inc. (Nasdaq: ALVR), a multiple Phase 3 clinical trial stage allogeneic T cell immunotherapy company, today reported financial results for the first quarter ended March 31, 2022. The company also shared progress across its virus-specific T cell (VST) programs, with its ...
Business Wire
5/5/2022 AlloVir Reports First Quarter 2022 Financial Results | Business Wire
WALTHAM, Mass.--( BUSINESS WIRE )--AlloVir, Inc. (Nasdaq: ALVR), a multiple Phase 3 clinical trial stage allogeneic T cell immunotherapy company, today reported financial results for the first quarter ended March 31, 2022. The company also shared progress across its virus-specific T cell (VST) programs, with its lead product, posoleucel ...
Business Wire
5/2/2022 T cell Immunotherapy Market is Anticipated to Reach US$ 7648.9 Million, at a Robust CAGR of 15.7% Between 2020-2026
The Infinium Global Research analyzes the T cell Immunotherapy Market over the period of 2020 to 2026. This report also provides detailed qualitative and quantitative analyses of the market dynamics, market size and future trends in global t cell immunotherapy market. It will help a lot of decision makers to ...
heraldkeeper.com
4/20/2022 FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir's Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients | Business Wire
WALTHAM, Mass.--( BUSINESS WIRE )--AlloVir (Nasdaq: ALVR), a late clinical-stage allogeneic T cell immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead investigational multi-virus-specific T cell therapy, posoleucel, for the prevention of clinically ...
Business Wire
4/19/2022 Verismo Therapeutics Expands Scientific Team to Advance its KIR-CAR Platform for the Treatment of Solid Tumors
... First-in-Human Clinical Trial for our KIR-CAR platform." Dr. Xu has extensive experience from process development, drug product characterization to translational studies in T cell immunotherapy. She served as an Associate Director of translational research in Product Development Laboratory, Center for Cellular Immunotherapies, at the University of Pennsylvania ...
PR Newswire
4/7/2022 Renowned Immunotherapy Expert Dr. Michael Kalos joins Anocca's Scientific Advisory Board
... T cell therapeutics, today announced the appointment of Dr. Michael Kalos to its Scientific Advisory Board (SAB). Dr. Kalos is an internationally recognised expert in T cell immunotherapy with over 25 years' experience at the cutting edge of cell therapy, oncology vaccines, and immuno-oncology. Michael was most recently Executive ...
PR Newswire
4/7/2022 Renowned Immunotherapy Expert Dr. Michael Kalos joins Anocca's Scientific Advisory Board
... T cell therapeutics, today announced the appointment of Dr. Michael Kalos to its Scientific Advisory Board (SAB). Dr. Kalos is an internationally recognised expert in T cell immunotherapy with over 25 years' experience at the cutting edge of cell therapy, oncology vaccines, and immuno-oncology. Michael was most recently Executive ...
Yahoo News